ScreenerHero

OCS Oculis Holding AG

NAS · US · Healthcare · Biotechnology · oculis.com
8.500USD-2.52%Mkt Cap: 523.50M $P/E: —

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product cand…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap523.50M USD
Enterprise Value312.52M USD
Revenue (TTM)1.17M USD
Gross Profit-55.56M USD
Net Income (TTM)-98.96M USD
Revenue/Share0.02 USD
Last Price8.500 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees60
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.39
PEG—
EV/EBITDA-3.63
EV/Revenue266.43
P/S457.84
P/B2.01
EPS (TTM)-1.74
EPS (Forward)-1.99
52W Range
8.3101% of range34.47
52W High34.47 USD
52W Low8.310 USD
Profitability
Gross Margin0.00%
Oper. Margin-7602.58%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-50.47%
ROA-41.94%
Growth
Revenue Growth18.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-66.30M USD
CapEx (TTM)1.39M USD
FCF Margin-3527.09%
FCF Yield-7.90%
Net Debt-225.78M USD
Net Debt/EBITDA2.63
Balance Sheet
Debt/Equity0.01
Current Ratio8.35
Quick Ratio8.24
Book Value/Sh4.34 USD
Cash/Share3.70 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.50 USD
Upside (mean)+329.5%
Target Range19.52 USD – 43.66 USD
19.52+329.5% to mean43.66
# Analysts10
Ownership
Shares Out.61.59M
Float52.41M
Insiders3.53%
Institutions47.54%
Short Interest
Short Ratio9.6d
Short % Float2.90%
Short % Out.2.52%
Shares Short1.55M
Short (prev mo.)1.46M
Technical
SMA 5011.41 (-25.5%)
SMA 20020.06 (-57.6%)
Beta0.27
S&P 52W Chg15.78%
Avg Vol (30d)236.03K
Avg Vol (10d)328.11K
Technical Indicators
RSI (14)25.4
MACD-0.9348
MACD Signal-0.8617
MACD Hist.-0.0731
BB Upper12.29 USD
BB Middle9.933 USD
BB Lower7.574 USD
BB Width47.50%
ATR (14)0.5372 USD
Vol Ratio (20d)0.64x